Pegaptanib (BioDeep_00000182152)
human metabolite blood metabolite
代谢物信息卡片
化学式: C22H44N3O10P (541.2764174)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 98.04%
分子结构信息
SMILES: COCCOC(=O)NCCCCC(C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC
InChI: InChI=1S/C22H44N3O10P/c1-31-15-17-33-21(27)24-13-9-7-11-19(25-22(28)34-18-16-32-2)20(26)23-12-8-5-4-6-10-14-35-36(3,29)30/h19H,4-18H2,1-3H3,(H,23,26)(H,24,27)(H,25,28)(H,29,30)
描述信息
S - Sensory organs > S01 - Ophthalmologicals > S01L - Ocular vascular disorder agents > S01LA - Antineovascularisation agents
同义名列表
5 个代谢物同义名
2,6-Bis({[hydroxy(2-methoxyethoxy)methylidene]amino})-N-(7-{[hydroxy(methyl)phosphoryl]oxy}heptyl)hexanimidate; ({7-[2,6-bis({[(2-methoxyethoxy)carbonyl]amino})hexanamido]heptyl}oxy)(methyl)phosphinic acid; {7-[2,6-bis({[(2-methoxyethoxy)carbonyl]amino})hexanamido]heptyl}oxy(methyl)phosphinic acid; 7-[2,6-Bis(2-methoxyethoxycarbonylamino)hexanoylamino]heptoxy-methylphosphinic acid; Pegaptanib
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Xueping Xie, Yuxin Zhang, Wenjuan Ma, Xiaoru Shao, Yuxi Zhan, Chenchen Mao, Bofeng Zhu, Yi Zhou, Hu Zhao, Xiaoxiao Cai. Potent anti-angiogenesis and anti-tumour activity of pegaptanib-loaded tetrahedral DNA nanostructure.
Cell proliferation.
2019 Sep; 52(5):e12662. doi:
10.1111/cpr.12662. [PMID: 31364793] - Noemi Manresa, Juana Mulero, Manuel Losada, Pilar Zafrilla. EFFECT OF PEGAPTANIB AND RANIBIZUMAB ON PLASMA AND VITREOUS HOMOCYSTEINE IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Retina (Philadelphia, Pa.).
2015 Sep; 35(9):1765-71. doi:
10.1097/iae.0000000000000552. [PMID: 25923955] - Claudio Campa. Effect of VEGF and anti-VEGF compounds on retinal pigment epithelium permeability: an in vitro study.
European journal of ophthalmology.
2013 Sep; 23(5):690-6. doi:
10.5301/ejo.5000248. [PMID: 23539459] - Claus Zehetner, Rudolf Kirchmair, Stefan Huber, Martina T Kralinger, Gerhard F Kieselbach. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
The British journal of ophthalmology.
2013 Apr; 97(4):454-9. doi:
10.1136/bjophthalmol-2012-302451. [PMID: 23385630] - Anthony S Basile, Matt Hutmacher, Dana Nickens, Jace Nielsen, Ken Kowalski, Lloyd Whitfield, Oishi Masayo, Masami Nakane. Population pharmacokinetics of pegaptanib in patients with neovascular, age-related macular degeneration.
Journal of clinical pharmacology.
2012 Aug; 52(8):1186-99. doi:
10.1177/0091270011412961. [PMID: 21947371] - Michael I Dorrell, Edith Aguilar, Ruth Jacobson, Oscar Yanes, Ray Gariano, John Heckenlively, Eyal Banin, G Anthony Ramirez, Mehdi Gasmi, Alan Bird, Gary Siuzdak, Martin Friedlander. Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress.
The Journal of clinical investigation.
2009 Mar; 119(3):611-23. doi:
10.1172/jci35977. [PMID: 19188685] - H L Deissler, G E Lang. [Effect of VEGF165 and the VEGF aptamer pegaptanib (Macugen) on the protein composition of tight junctions in microvascular endothelial cells of the retina].
Klinische Monatsblatter fur Augenheilkunde.
2008 Oct; 225(10):863-7. doi:
10.1055/s-2008-1027767. [PMID: 18951306] - Martin S Spitzer, Efdal Yoeruek, Ana Sierra, Barbara Wallenfels-Thilo, Ulrich Schraermeyer, Bernhard Spitzer, Karl U Bartz-Schmidt, Peter Szurman. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie.
2007 Dec; 245(12):1837-42. doi:
10.1007/s00417-007-0568-7. [PMID: 17347807] - Jeffrey W-D Foy, Kay Rittenhouse, Marlene Modi, Manju Patel. Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
2007 Oct; 23(5):452-66. doi:
10.1089/jop.2006.0149. [PMID: 17900226] - Rajendra S Apte, Marlene Modi, Harvey Masonson, Manju Patel, Lloyd Whitfield, Anthony P Adamis. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
Ophthalmology.
2007 Sep; 114(9):1702-12. doi:
10.1016/j.ophtha.2007.02.021. [PMID: 17509689]